PEPFAR is encouraged by today’s announcement by Unitaid, the Global Fund to Fight AIDS, Tuberculosis and Malaria, and global biopharmaceutical company Sanofi that reduces the price of rifapentine, an FDA-approved tuberculosis preventive treatment (TPT), to approximately $15 for a three-month treatment course. This price reduction makes a shorter, safer, and affordable TPT regimen more available to low- and middle-income countries with high burdens of tuberculosis (TB) and HIV.
TB causes the most deaths among people with HIV worldwide, accounting for more than 250,000 deaths in 2018, and is the greatest infectious disease killer globally. TPT is life-saving. PEPFAR has set a goal of treating nine million people who are living with HIV with TPT and significantly increasing our resource investments in TPT over the next two years.
Despite today’s announcement, we remain concerned that the current annual production capacity of rifapentine would only be sufficient to treat a fraction of the people living with HIV who need it.